Airfinity is a disease forecasting company specialising in infectious diseases, cardiovascular, metabolic, and renal diseases and other critical areas including RNA. It tracks, predicts, and simulates population level disease outcomes in real time to inform decisions that can increase the global life span.
Founded in 2015, Airfinity was created to systematically capture, and structure new science disseminated at conferences, a valuable yet highly fragmented dataset. Through working with medical associations, research institutions and pharma companies, Airfinity built on this success to create the world’s first dedicated COVID-19 platform in 2020.
Office Address: 134 Wigmore St,London W1U 3SE, UK
